The Evolving Landscape of Multiple Sclerosis Research

Multiple Sclerosis (MS) Awareness Week provides an opportunity to highlight the advancements being made in MS research and treatment. As an organisation committed to improving the lives of those affected by MS, ICON plays a crucial role in conducting clinical trials that help develop new and improved treatments.

This blog shares insights from our dedicated CNS & Rare Diseases Project Management Leads and provides context on the current state of MS research and treatment.

Understanding Multiple Sclerosis

Multiple Sclerosis is a chronic autoimmune disease that affects the central nervous system, primarily the brain and spinal cord. In MS, the immune system mistakenly attacks the protective covering of nerve fibres, called myelin, leading to communication problems between the brain and the rest of the body. This damage can result in a wide range of symptoms, including fatigue, difficulty walking, numbness, tingling, weakness, vision problems, and cognitive changes.
MS typically affects young adults between the ages of 20 and 40, with a higher prevalence amongst women. The disease follows different patterns in different individuals, making it a complex condition to study and treat.

The Evolution of MS Treatment

The landscape of MS treatment has evolved significantly over the past few decades. In the early 1990s, the first disease-modifying therapies were approved, marking a significant milestone in MS treatment. Before these medications, treatment primarily focused on managing symptoms rather than addressing the underlying disease process.
Today, there are over 20 approved treatments for MS, offering patients more options than ever before. These treatments fall into several categories:
Injectable medications
Oral medications
Infusion therapies
Symptomatic treatments
Each category offers different benefits and considerations for patients, allowing for more personalised treatment approaches.

The Critical Role of Clinical Trials

Clinical trials are the cornerstone of developing new MS treatments. Fiona Purcell, Director of Project Management for CNS & Rare Diseases at ICON, highlights the significance of this work:
"The clinical trial I work on in MS is a phase III large global study investigating and comparing the safety and efficacy of a new class of treatment in Multiple Sclerosis compared to an existing approved treatment for MS. Data to date indicates that our investigational medicinal product has a favourable safety profile and is well tolerated, therefore having the potential to improve treatment side-effects for MS patients without compromising efficacy."
This work is particularly important because, as Fiona notes, MS typically affects young adults with a higher prevalence in females. Treatments that are effective, well-tolerated, and conveniently administered are crucial for allowing patients to maintain their day-to-day activities, especially during non-relapsing periods.

Challenges in MS Research

Despite significant progress, MS research faces numerous challenges. Nikolay Karpachev, who works with Fiona as Senior Director of Project Management for CNS & Rare Diseases at ICON, identifies several key obstacles:
Recruitment and retention: High competition for trial participants, varying MS prevalence across regions, and dropouts due to side effects or waning interest in long-term studies create significant hurdles.
Disease heterogeneity: MS presents with many forms, symptoms, and progression patterns, making it difficult to develop one-size-fits-all treatments.
Cost considerations: The necessity for long-term patient follow-up - often extending for years -drives up research costs.
Study design complexities: Decisions about placebo versus comparator designs and the ethical limitations of placebo-controlled studies require careful consideration.
Data quality concerns: Ensuring reliable data through appropriate electronic clinical outcome assessments (eCOA), biomarkers, blinding plans, and rater certification is an ongoing challenge.
These challenges underscore the complexity of MS research and the dedication required to advance treatment options.

Looking to the Future

Despite these challenges, the future of MS research holds tremendous promise. Nikolay shares an optimistic perspective:
"The future of MS clinical research is very promising with the goal to improve early diagnosis and develop targeted and personalised innovative therapies. That includes stem cell therapies, immunotherapies, biomarker development for early diagnosis and monitoring. The new directions also include neuroprotection, microbiome research, and MS vaccines."
Additionally, biosimilars represent a significant area for research, as they can provide therapeutic benefits of reference biologic drugs to underserved populations and regions with limited healthcare resources.

Emerging Research Areas

Several innovative approaches are currently being explored in MS research:
Remyelination therapies: Researchers are investigating treatments that could help repair damaged myelin, potentially restoring lost function.
Precision medicine: The development of biomarkers to identify which patients will respond best to specific treatments may lead to more personalised treatment approaches.
Microbiome research: Growing evidence suggests that gut bacteria may play a role in MS development and progression, opening new avenues for treatment.
Neuroprotective strategies: Approaches aimed at protecting neurones from damage may help slow disease progression.
Advanced imaging techniques: New imaging methods are improving our ability to monitor disease activity and treatment response.

Conclusion

As we observe MS Awareness Week, it's important to recognise both the challenges and the progress in MS research. The dedicated work of researchers at organisations like ICON is driving advancements that improve the lives of people living with MS.
The future of MS treatment is bright, with promising new approaches on the horizon. Through continued research, collaboration, and innovation, we move closer to better outcomes for all those affected by MS.
Our team remains committed to advancing MS research through rigorous clinical trials, driven by the goal of developing treatments that not only manage symptoms but potentially modify the course of the disease. Together, we are making a difference in the lives of people living with MS.

List #1

Related jobs at ICON

Site Activation Partner

Salary

Location

Canada, Burlington

Location

Burlington

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Study Start Up

Job Type

Permanent

Description

We are currently seeking a Study Start Up Associate I to join our diverse and dynamic team. As a Study Start Up Associate I at ICON, you will play a pivotal role in facilitating the initiation of clin

Reference

JR147906

Expiry date

01/01/0001

Author

Kala Murphy

Author

Kala Murphy

Read more Shortlist Save this role

Global Study Manager

Salary

Location

Canada

Location

Canada

Remote Working

Remote or Office

Business Area

ICON Strategic Solutions

Job Categories

Clinical Trial Management

Job Type

Permanent

Description

We are currently seeking a Global Study Lead to join our diverse and dynamic team. As the Global Study Lead, you will hold a crucial role in ensuring the successful delivery of all clinical aspects of

Reference

JR147460

Expiry date

01/01/0001

Author

Kala Murphy

Author

Kala Murphy

Read more Shortlist Save this role

Global Study Manager

Salary

Location

Canada

Location

Canada

Remote Working

Remote or Office

Business Area

ICON Strategic Solutions

Job Categories

Clinical Trial Management

Job Type

Permanent

Description

Reference

JR147461

Expiry date

01/01/0001

Author

Kala Murphy

Author

Kala Murphy

Read more Shortlist Save this role

Senior Clinical Scientist

Salary

Location

US, Blue Bell (ICON)

Location

Montreal

Burlington

Blue Bell

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Scientist

Job Type

Permanent

Description

Senior Clinical ScientistWhat you will be doing: May lead or support a study or studies, depending on size/complexity. If lead, accountable for the clinical/scientific execution of the protocol.As le

Reference

JR148116

Expiry date

01/01/0001

Author

Monica Hawkins

Author

Monica Hawkins

Read more Shortlist Save this role

View all

List #1

Impactful work. Meaningful careers. Quality rewards.

At ICON, our employees are our greatest strength. That’s why we are committed to empowering you to live your best life, both inside and outside of work. Whether your ambition is lead a global team, become a deep scientific or technical expert, work in-house with our customers or gain experience in a variety of different ICON functions, we will support you in realising your full potential.
Learn more about Our Culture at ICON

About Icon

Overview of Service Lines

Full Service

ICON Strategic Solutions

Global Business Services

Global Office Locator

Inclusion & Belonging

ICON Cares - ESG

Building a Successful Clinical Research Resume

Landing Your First Job in Clinical Research

graduate What does full service mean for you?

Multiple Sclerosis Awareness Week: Progress and Hope